ArticleFrontiers in endocrinology2025
An investigation of the pattern and mechanism of comorbidity in patients with Hashimoto's thyroiditis.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate comorbidity patterns and potential pathogenic mechanisms in patients with Hashimoto's thyroiditis (HT). Methods: Patients with HT who visited the outpatient clinic of the Thyroid Department at Dongzhimen Hospital, Beijing University of Chinese Medicine, between June 2021 and December 2024 were included. Association rule analysis and logistic regression analysis were performed using SPSS 25.0 and SPSS Modeler 18.0 to identify comorbidity patterns. Disease targets were screened using the GeneCards database, and protein interaction networks for intersecting targets were constructed using STRING and Cytoscape. GO function and KEGG pathway enrichment analyses were performed with Metascape to uncover relevant targets and potential pathways associated with comorbidities in patients with HT. Results: Among 429 patients with HT, 348 had comorbidities, resulting in a comorbidity prevalence of 81.19%. Association rule analysis identified thyroid nodules (TN) as the core binary comorbidity. The combination of TN and hyperplasia of the mammary gland (HMG) was central to ternary comorbidities, while the trio of TN, HMG, and uterine leiomyomas (UL) characterized quaternary comorbidities. Being a woman and advancing age were associated with increased risk of comorbidities, whereas levothyroxine sodium (L-T4) therapy was linked to reduced risk. Core targets associated with comorbidity prediction included AKT1, TP53, EGFR, INS, and TNF. Key pathways involved were the cancer pathway and PI3K-Akt signaling pathway. Conclusion: The high prevalence of comorbidities in patients with HT warrants increased clinical attention within the medical community.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.